Circulating microRNA-21 as a potential diagnostic marker for colorectal cancer: A meta-analysis

Yu,Wei; Wang,Zhanhuai; Shen,Li; Wei,Qichun

doi:10.3892/mco.2015.702

Circulating microRNA-21 as a potential diagnostic marker for colorectal cancer: A meta-analysis

Authors:
- Wei Yu
- Zhanhuai Wang
- Li Shen
- Qichun Wei
View Affiliations

Affiliations: Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, P.R. China, Department of Surgical Oncology, Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, P.R. China
Published online on: December 8, 2015 https://doi.org/10.3892/mco.2015.702
Pages: 237-244

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA‑21 (miR‑21) is overexpressed in the serum of patients with colorectal cancer (CRC), suggesting that miR‑21 is a promising diagnostic biomarker for CRC. Therefore, a meta‑analysis was performed to assess the diagnostic value of serum miR‑21 in CRC patients. This meta‑analysis included 9 studies with 746 CRC patients and 476 healthy controls. Two independent researchers identified and extracted study characteristics from eligible studies that were searched from literature databases. The quality of the eligible studies was assessed in accordance with the Quality Assessment of Diagnostic Accuracy Studies. Bivariate and hierarchical summary receiver operating characteristic models were used in the meta‑analysis. The pooled sensitivity and specificity were 72% [95% confidence interval (CI), 62‑80] and 85% (95% CI, 80‑88), respectively. The pooled positive‑ and negative‑likelihood ratios were 4.65 (95% CI, 3.42‑6.33) and 0.33 (95% CI, 0.24‑0.47), respectively. The diagnostic odds ratio value was 14.03 (95% CI, 7.65‑25.74), and the area under the summary receiver operator characteristic curve was 0.87. The present results indicated that miR‑21 has a potential diagnostic value with moderate sensitivity and good specificity for CRC. Further prospective studies must be conducted to evaluate the diagnostic accuracy of miR‑21.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
3	O'Connell JB, Maggard MA and Ko CY: Colon cancer survival rates with the new American joint committee on cancer sixth edition staging. J Natl Cancer Inst. 96:1420–1425. 2004. View Article : Google Scholar : PubMed/NCBI
4	Collins JF, Lieberman DA, Durbin TE and Weiss DG: Veterans Affairs Cooperative Study #380 Group: Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination. A comparison with recommended sampling practice. Ann Intern Med. 142:81–85. 2005. View Article : Google Scholar : PubMed/NCBI
5	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
6	Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
7	Wiemer EA: The role of microRNAs in cancer: N o small matter. Eur J Cancer. 43:1529–1544. 2007. View Article : Google Scholar : PubMed/NCBI
8	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
9	Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
10	Duttagupta R, Jiang R, Gollub J, Getts RC and Jones KW: Impact of cellular miRNAs on circulating miRNA biomarker signatures. PloS one. 6:e207692011. View Article : Google Scholar : PubMed/NCBI
11	Schetter AJ and Harris CC: Plasma microRNAs: A potential biomarker for colorectal cancer? Gut. 58:1318–1319. 2009. View Article : Google Scholar : PubMed/NCBI
12	Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM and Kleijnen J: The development of QUADAS, A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 3:252003. View Article : Google Scholar : PubMed/NCBI
13	Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM and Zwinderman AH: Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 58:982–990. 2005. View Article : Google Scholar : PubMed/NCBI
14	Rutter CM and Gatsonis CA: A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med. 20:2865–2884. 2001. View Article : Google Scholar : PubMed/NCBI
15	Moses LE, Shapiro D and Littenberg B: Combining independent studies of a diagnostic test into a summary ROC curve, Data-analytic approaches and some additional considerations. Stat Med. 12:1293–1316. 1993. View Article : Google Scholar : PubMed/NCBI
16	Higgins JP, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ. 327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
17	Dinnes J, Deeks J, Kirby J and Roderick P: A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess. 9(iii): 1–113. 2005. View Article : Google Scholar : PubMed/NCBI
18	Zamora J, Abraira V, Muriel A, Khan K and Coomarasamy A: Meta-DiSc: A software for meta-analysis of test accuracy data. BMC Med Res Methodol. 6:312006. View Article : Google Scholar : PubMed/NCBI
19	Basati G, Razavi Emami A, Abdi S and Mirzaei A: Elevated level of microRNA-21 in the serum of patients with colorectal cancer. Medical Oncol. 31:2052014. View Article : Google Scholar
20	Wang B and Zhang Q: The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol. 138:1659–1666. 2012. View Article : Google Scholar : PubMed/NCBI
21	Liu GH, Zhou ZG, Chen R, Wang MJ, Zhou B, Li Y and Sun XF: Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol. 34:2175–2181. 2013. View Article : Google Scholar : PubMed/NCBI
22	Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, Gunji T, Ohta H, Okamoto H, Sonoda H, et al: Circulating exosomal microRNAs as biomarkers of colon cancer. PloS one. 9:e929212014. View Article : Google Scholar : PubMed/NCBI
23	Luo X, Stock C, Burwinkel B and Brenner H: Identification and evaluation of plasma microRNAs for early detection of colorectal cancer. PloS One. 8:e628802013. View Article : Google Scholar : PubMed/NCBI
24	Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR and Goel A: Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 105:849–859. 2013. View Article : Google Scholar : PubMed/NCBI
25	Kanaan Z, Rai SN, Eichenberger MR, Roberts H, Keskey B, Pan J and Galandiuk S: Plasma miR-21: A potential diagnostic marker of colorectal cancer. Ann Surg. 256:544–551. 2012. View Article : Google Scholar : PubMed/NCBI
26	Zhang H, Li P, Ju H, Pesta M, Kulda V, Jin W, Cai M, Liu C, Wu H, Xu J, et al: Diagnostic and prognostic value of micro RNA-21 in colorectal cancer: An original study and individual participant data meta-analysis. Cancer Epidemiol Biomarkers Prev. 23:2783–2792. 2014. View Article : Google Scholar : PubMed/NCBI
27	Du M, Liu S, Gu D, Wang Q, Zhu L, Kang M, Shi D, Chu H, Tong N, Chen J, et al: Clinical potential role of circulating microRNAs in early diagnosis of colorectal cancer patients. Carcinogenesis. 35:2723–2730. 2014. View Article : Google Scholar : PubMed/NCBI
28	Rosenfeld RM and Shiffman RN: Clinical practice guidelines: A manual for developing evidence-based guidelines to facilitate performance measurement and quality improvement. Otolaryngol Head Neck Surg. 135((Suppl 4)): S1–S28. 2006. View Article : Google Scholar : PubMed/NCBI
29	Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
30	Selcuklu SD, Donoghue MT and Spillane C: miR-21 as a key regulator of oncogenic processes. Biochem Soc Trans. 37:918–925. 2009. View Article : Google Scholar : PubMed/NCBI
31	Zeng Z, Wang J, Zhao L, Hu P, Zhang H, Tang X, He D, Tang S and Zeng Z: Potential role of microRNA-21 in the diagnosis of gastric cancer, A meta-analysis. PloS One. 8:e732782013. View Article : Google Scholar : PubMed/NCBI
32	Yang X, Guo Y, Du Y, Yang J, Li S, Liu S, Li K and Zhang D: Serum microRNA-21 as a diagnostic marker for lung carcinoma, A systematic review and meta-analysis. PloS One. 9:e974602014. View Article : Google Scholar : PubMed/NCBI
33	Krichevsky AM and Gabriely G: miR-21: A small multi-faceted RNA. J Cell Mol Med. 13:39–53. 2009. View Article : Google Scholar : PubMed/NCBI